Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-21

"To make the comment about making difficult decisions and trade offs it would indicate to me that something is afoot which is yet to be divulged."

Staffing costs $1.9m per quarter, $296k directors fees, Admin and Corporate $300k, "Consultant to Board" no mention. I would have thought that there are some not so hard decisions to make there. "R&D costs expected to reduce" and we have also been told some things are going to the back burner.
"Starpharma is focused on managing its resources to extend the Company’s cash runway as it continues to prioritise the monetisation of its assets". Presumably that means more business class fares to U.S.?
Absent the usual list from AB does anyone really know what is going on in there?